High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study

Dai Chihara, Koji Izutsu, Eisei Kondo, Rika Sakai, Shuichi Mizuta, Kenji Yokoyama, Hiroto Kaneko, Koji Kato, Yuichi Hasegawa, Takaaki Chou, Hiroyuki Sugahara, Hideho Henzan, Hisashi Sakamaki, Ritsuro Suzuki, Junji Suzumiya

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The number of elderly patients with diffuse large Bcell lymphoma (DLBCL) continues to increase but the data regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients, ages 60years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64years (range, 60 to 78). To evaluate the impact of age at ASCT, patients were classified into 3 groups: those between the ages of 60 to 64, 65 to 69, and 70years or over. Overall nonrelapse mortality (NRM) at day 100, 1year, and 2years was 4.1%, 5.9% and 7.7%, respectively. NRM did not significantly differ among age groups (P=.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48% and 58%, respectively. PFS and OS were significantly longer in patients 60 to 64years old; however, the survival rate was acceptable even in those 70 or over, with a 2-year OS of 46%. ASCT is feasible in selected elderly patients and age alone should not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.

Original languageEnglish
Pages (from-to)684-689
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Stem Cell Transplantation
Retrospective Studies
Drug Therapy
Disease-Free Survival
Survival
Mortality
Lymphoma
Cell Transplantation
Japan
Survival Rate
Age Groups
Databases
Morbidity

Keywords

  • Autologous stem cell transplantation
  • Diffuse large Bcell lymphoma
  • Elderly patients
  • Relapse/refractory

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma : A Nationwide Retrospective Study. / Chihara, Dai; Izutsu, Koji; Kondo, Eisei; Sakai, Rika; Mizuta, Shuichi; Yokoyama, Kenji; Kaneko, Hiroto; Kato, Koji; Hasegawa, Yuichi; Chou, Takaaki; Sugahara, Hiroyuki; Henzan, Hideho; Sakamaki, Hisashi; Suzuki, Ritsuro; Suzumiya, Junji.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 5, 2014, p. 684-689.

Research output: Contribution to journalArticle

Chihara, D, Izutsu, K, Kondo, E, Sakai, R, Mizuta, S, Yokoyama, K, Kaneko, H, Kato, K, Hasegawa, Y, Chou, T, Sugahara, H, Henzan, H, Sakamaki, H, Suzuki, R & Suzumiya, J 2014, 'High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study', Biology of Blood and Marrow Transplantation, vol. 20, no. 5, pp. 684-689. https://doi.org/10.1016/j.bbmt.2014.01.025
Chihara, Dai ; Izutsu, Koji ; Kondo, Eisei ; Sakai, Rika ; Mizuta, Shuichi ; Yokoyama, Kenji ; Kaneko, Hiroto ; Kato, Koji ; Hasegawa, Yuichi ; Chou, Takaaki ; Sugahara, Hiroyuki ; Henzan, Hideho ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Suzumiya, Junji. / High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma : A Nationwide Retrospective Study. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 5. pp. 684-689.
@article{7bd1d4ff410943de8f0dce9871273b26,
title = "High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study",
abstract = "The number of elderly patients with diffuse large Bcell lymphoma (DLBCL) continues to increase but the data regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients, ages 60years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64years (range, 60 to 78). To evaluate the impact of age at ASCT, patients were classified into 3 groups: those between the ages of 60 to 64, 65 to 69, and 70years or over. Overall nonrelapse mortality (NRM) at day 100, 1year, and 2years was 4.1{\%}, 5.9{\%} and 7.7{\%}, respectively. NRM did not significantly differ among age groups (P=.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48{\%} and 58{\%}, respectively. PFS and OS were significantly longer in patients 60 to 64years old; however, the survival rate was acceptable even in those 70 or over, with a 2-year OS of 46{\%}. ASCT is feasible in selected elderly patients and age alone should not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.",
keywords = "Autologous stem cell transplantation, Diffuse large Bcell lymphoma, Elderly patients, Relapse/refractory",
author = "Dai Chihara and Koji Izutsu and Eisei Kondo and Rika Sakai and Shuichi Mizuta and Kenji Yokoyama and Hiroto Kaneko and Koji Kato and Yuichi Hasegawa and Takaaki Chou and Hiroyuki Sugahara and Hideho Henzan and Hisashi Sakamaki and Ritsuro Suzuki and Junji Suzumiya",
year = "2014",
doi = "10.1016/j.bbmt.2014.01.025",
language = "English",
volume = "20",
pages = "684--689",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

T2 - A Nationwide Retrospective Study

AU - Chihara, Dai

AU - Izutsu, Koji

AU - Kondo, Eisei

AU - Sakai, Rika

AU - Mizuta, Shuichi

AU - Yokoyama, Kenji

AU - Kaneko, Hiroto

AU - Kato, Koji

AU - Hasegawa, Yuichi

AU - Chou, Takaaki

AU - Sugahara, Hiroyuki

AU - Henzan, Hideho

AU - Sakamaki, Hisashi

AU - Suzuki, Ritsuro

AU - Suzumiya, Junji

PY - 2014

Y1 - 2014

N2 - The number of elderly patients with diffuse large Bcell lymphoma (DLBCL) continues to increase but the data regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients, ages 60years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64years (range, 60 to 78). To evaluate the impact of age at ASCT, patients were classified into 3 groups: those between the ages of 60 to 64, 65 to 69, and 70years or over. Overall nonrelapse mortality (NRM) at day 100, 1year, and 2years was 4.1%, 5.9% and 7.7%, respectively. NRM did not significantly differ among age groups (P=.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48% and 58%, respectively. PFS and OS were significantly longer in patients 60 to 64years old; however, the survival rate was acceptable even in those 70 or over, with a 2-year OS of 46%. ASCT is feasible in selected elderly patients and age alone should not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.

AB - The number of elderly patients with diffuse large Bcell lymphoma (DLBCL) continues to increase but the data regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484 patients, ages 60years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to 2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64years (range, 60 to 78). To evaluate the impact of age at ASCT, patients were classified into 3 groups: those between the ages of 60 to 64, 65 to 69, and 70years or over. Overall nonrelapse mortality (NRM) at day 100, 1year, and 2years was 4.1%, 5.9% and 7.7%, respectively. NRM did not significantly differ among age groups (P=.60). Two-year progression-free survival (PFS) and overall survival (OS) were 48% and 58%, respectively. PFS and OS were significantly longer in patients 60 to 64years old; however, the survival rate was acceptable even in those 70 or over, with a 2-year OS of 46%. ASCT is feasible in selected elderly patients and age alone should not be a contraindication for ASCT. Eligibility should be individualized and identification of a subset of elderly patients at high risk of treatment-related morbidity or mortality warrants investigation.

KW - Autologous stem cell transplantation

KW - Diffuse large Bcell lymphoma

KW - Elderly patients

KW - Relapse/refractory

UR - http://www.scopus.com/inward/record.url?scp=84897960368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897960368&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.01.025

DO - 10.1016/j.bbmt.2014.01.025

M3 - Article

C2 - 24492141

AN - SCOPUS:84897960368

VL - 20

SP - 684

EP - 689

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -